{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T13:27:43Z","timestamp":1778851663947,"version":"3.51.4"},"reference-count":8,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.pathol.2021.06.124","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T09:57:07Z","timestamp":1632477427000},"page":"384-386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Progression of mesothelioma in situ to invasive disease 4 years and 10 months after initial diagnosis"],"prefix":"10.1016","volume":"54","author":[{"given":"Sonja","family":"Klebe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2021.06.124_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/1310478","article-title":"Malignant mesothelioma, BAP1 immunohistochemistry, and VEGFA: does BAP1 have potential for early diagnosis and assessment of prognosis?","volume":"2017","author":"Pulford","year":"2017","journal-title":"Dis Markers"},{"key":"10.1016\/j.pathol.2021.06.124_bib2","first-page":"151","article-title":"The concept of mesothelioma in situ: implications for diagnosis and histogenesis","volume":"9","author":"Whitaker","year":"1992","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.pathol.2021.06.124_bib3","series-title":"WHO Classification of Tumours Editorial Board. Thoracic Tumours. 5th ed.","year":"2021"},{"key":"10.1016\/j.pathol.2021.06.124_bib4","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.pathol.2020.06.010","article-title":"Malignant mesothelioma in situ: diagnostic and clinical considerations","volume":"52","author":"Pulford","year":"2020","journal-title":"Pathology"},{"key":"10.1016\/j.pathol.2021.06.124_bib5","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00428-019-02674-x","article-title":"Malignant mesothelioma in situ diagnosed by methylthioadenosine phosphorylase loss and homozygous deletion of CDKN2A: a case report","volume":"476","author":"Minami","year":"2020","journal-title":"Virchows Arch"},{"key":"10.1016\/j.pathol.2021.06.124_bib6","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41379-019-0347-0","article-title":"Malignant mesothelioma in situ: morphologic features and clinical outcome","volume":"33","author":"Churg","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2021.06.124_bib7","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jtho.2020.03.014","article-title":"Malignant mesothelioma in situ: clinical and pathologic implications","volume":"15","author":"Churg","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.pathol.2021.06.124_bib8","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.pathol.2020.12.005","article-title":"The concept of mesothelioma in situ, with consideration of its potential impact on cytology diagnosis","volume":"53","author":"Klebe","year":"2021","journal-title":"Pathology"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302521004608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302521004608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T23:13:46Z","timestamp":1648595626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302521004608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0031302521004608"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2021.06.124","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progression of mesothelioma in situ to invasive disease 4 years and 10 months after initial diagnosis","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2021.06.124","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}